CMB 401

Drug Profile

CMB 401

Alternative Names: anti-PEM monoclonal antibody calicheamicin; CDP 671; hcT.MO1 calicheamicin; hCTMO1-calicheamicin; LLE 33288

Latest Information Update: 02 Feb 2000

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celltech Group
  • Class Cytostatic antibiotics; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 02 Feb 2000 Medeva has been merged into Celltech Chiroscience, which is now called Celltech Group
  • 16 Dec 1999 Investigation in Non-small cell lung cancer in United Kingdom (IV-infusion)
  • 16 Dec 1999 Investigation in Non-small cell lung cancer in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top